Defense Dept. Funds Ketamine Study For PTSD Treatment
A DOD Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans. The intranasal racemic ketamine was developed by biotech company Seelos Therapeutics (NASDAQ:SEEL).
The new Phase 2 study will use an adaptive platform trial design involving a 30-day screening period, a 12-week treatment period, and a four-week follow-up to assess safety, tolerability and efficacy of multiple doses of SLS-002 paired with therapy. Read more HERE.
Cybin's Novel Psilocybin Topline Data
Next-generation psychedelics biotech Cybin Inc...
Login or create a forever free account to read this news
Sign up/Log in